Cambridge Cognition wins new £0.5m contract for cognitive at home testing

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a contract with a new pharmaceutical client to provide cognitive assessments in an at-home clinical trial.  The contract is worth approximately £0.5 million with most of the revenue expected to be recognised in 2021.

The COVID-19 pandemic has accelerated interest in virtual or decentralised clinical trials, with more assessments being planned at home and therefore out of the clinic setting.  To date there are just under 2,500 publications validating the Company’s CANTAB™ cognitive assessments.  While CANTAB™ has been used for many years in clinics, with the assessment being overseen by clinical staff, use at home has been growing, supported by evidence showing that performance is comparable.1

This clinical trial aims to use CANTAB™ to assess patients’ cognition from the comfort of their homes.  The trial is being sponsored by a leading pharmaceutical company with a pipeline of CNS drugs that the Company anticipates may benefit from cognitive assessments. 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

“We are delighted to have secured this contract and to be supporting another major pharmaceutical company to assess cognition in patients’ homes.  This is a trend that we expect to continue and will therefore provide more growth opportunities for Cambridge Cognition in the future.”

References

1.     Backx R, Skirrow C, Dente P, Barnett JH, Cormack FK. Comparing Web-Based and Lab-Based Cognitive Assessment Using CANTAB™. J Med Internet Res 2020;22(8):e16792. doi: 10.2196/16792

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition – An excellent year for the company (Interview)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk to discuss preliminary results for 2020. Matthew talks us through the highlights, explains how the company performed during the pandemic, where sales orders across the portfolio came from, progress

Cambridge Cognition Holdings

Cambridge Cognition Strong financial performance revenues up 34%

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a positive trading update and notice of results for the year ended 31 December 2020, together with details of a forthcoming change to

Cambridge Cognition Holdings

Cambridge Cognition wins new £750,000 digital health contract

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a new contract providing cognitive tests and electronic clinical outcome assessments for an Alzheimer’s trial. The total